Genex Pharmaceutical Inc (GENX) Fair Value & Analysis
Healthcare · US · Market cap $111K
Genex Pharmaceutical Inc
GENX · US
Fair value as of: Aug 18, 2026
From 20 valuation models · updated today
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from $0.0001 (bear) to $0.0001 (bull), base $0.0001. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 47/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.
How to read this chart
60‑month range $0.0001 – $0.0248 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 18, 2026.
Analysis
Genex Pharmaceutical Inc (GENX) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Genex Pharmaceutical Inc generated revenue of $3.2M at a net margin of 10.6%. Revenue grew 31.8% year over year. It earns a return on equity of 7.8%. Fundamentals as of Aug 18, 2026
The share trades about 50% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, GENX screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 20 models by family
Widest divergence: DCF Models ($0.0001) versus DCF Models ($0.0001). Highest evidence: Growth DCF (80).
Notify me when GENX reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People's Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes its medical devices to approximately 500 hospitals, as well as to other medical device customers. Genex Pharmaceutical, Inc.
Full company description
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People's Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes its medical devices to approximately 500 hospitals, as well as to other medical device customers. Genex Pharmaceutical, Inc. was founded in 2003 and is headquartered in Tianjin, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2003 – FY2007 · reported fiscal years
Genex Pharmaceutical Inc reported revenue of $3.2M in FY2007 versus $3.5K in FY2003, a compound +452.1%/yr. Reported net income was $343K in FY2007.
Watch GENX: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Genex Pharmaceutical Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Genex Pharmaceutical Inc (GENX) overvalued or undervalued?
What is the fair value of GENX?
What is the quality score of GENX?
What is the revenue of Genex Pharmaceutical Inc (GENX)?
What is the net profit margin of GENX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Genex Pharmaceutical Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.